Switch to:

Corvus Pharmaceuticals EBIT

: $-46.99 Mil (TTM As of Jun. 2020)
View and export this data going back to 2016. Start your Free Trial

Corvus Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2020 was $-10.77 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2020 was $-46.99 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Corvus Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2020 was -909.28%. Corvus Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2020 was -1,313.85%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Corvus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2020 was -84.45%.


Corvus Pharmaceuticals EBIT Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Corvus Pharmaceuticals Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EBIT Premium Member Only -13.77 -36.98 -56.52 -49.22 -48.85

Corvus Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.60 -11.51 -11.44 -13.27 -10.77

Corvus Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2020 was -11.513 (Sep. 2019 ) + -11.44 (Dec. 2019 ) + -13.269 (Mar. 2020 ) + -10.767 (Jun. 2020 ) = $-46.99 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Corvus Pharmaceuticals  (NAS:CRVS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Corvus Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2020 is calculated as:

ROC % (Q: Jun. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2020 ) + Invested Capital (Q: Jun. 2020 ))/ count )
=-43.068 * ( 1 - 0% )/( (4.881 + 4.592)/ 2 )
=-43.068/4.7365
=-909.28 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2020) data.

2. Joel Greenblatt's definition of Return on Capital:

Corvus Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2020 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2020 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2020  Q: Jun. 2020
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-43.068/( ( (3.441 + max(-9.823, 0)) + (3.115 + max(-9.402, 0)) )/ 2 )
=-43.068/( ( 3.441 + 3.115 )/ 2 )
=-43.068/3.278
=-1,313.85 %

where Working Capital is:

Working Capital(Q: Mar. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.962) - (10.785 + 0 + 0)
=-9.823

Working Capital(Q: Jun. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.175) - (10.577 + 0 + 0)
=-9.402

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2020) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Corvus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2020 )
=-46.989/55.642
=-84.45 %

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Corvus Pharmaceuticals EBIT Related Terms


Corvus Pharmaceuticals EBIT Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)